The window of opportunity on a takeover at $1B or less may be shut out very quickly. Shares on issue post capital raise are 1,105,000 (expected), so offer would be at around the 90c mark or in the vicinity of a 50% premium to the share price when it reopens to trading. Nothing to sneeze at but given the circumstances of a heavily cashed up explorer, highly prospective tenement, now revealing high grade and generally under-explored at depth, an aggressive (nothing to lose) management style and a rampaging POG, I would humbly suggest a 50% premium maybe not be enough at this opportune time for Spartan.
Next assays will likely tell the story. More good hits at NN and confirmation that Pepper is not a one hit wonder and we are off to the races - the 60 and 70cent levels could be taken out in a couple of sessions imo. Of course, if the assays don’t pan out as we’d like, a 90c takeover would look very appealing.
My opinions only.
- Forums
- ASX - By Stock
- Ann: A$80m Fully Underwritten Equity Raising to Accelerate Explor
SPR
spartan resources limited
Add to My Watchlist
1.25%
!
$1.97

The window of opportunity on a takeover at $1B or less may be...
Featured News
Add to My Watchlist
What is My Watchlist?
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
|
|||||
Last
$1.97 |
Change
-0.025(1.25%) |
Mkt cap ! $2.524B |
Open | High | Low | Value | Volume |
$2.01 | $2.05 | $1.95 | $66.88M | 33.90M |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
5 | 77974 | $1.96 |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
$1.98 | 85766 | 5 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
5 | 77974 | 1.955 |
6 | 52573 | 1.950 |
1 | 18392 | 1.945 |
1 | 388 | 1.930 |
4 | 3274 | 1.900 |
Price($) | Vol. | No. |
---|---|---|
1.980 | 85766 | 5 |
1.985 | 36091 | 2 |
1.990 | 18392 | 1 |
2.050 | 16500 | 2 |
2.060 | 5001 | 2 |
Last trade - 16.10pm 27/06/2025 (20 minute delay) ? |
Featured News
SPR (ASX) Chart |
The Watchlist
PAR
PARADIGM BIOPHARMACEUTICALS LIMITED..
Paul Rennie, MD & Founder
Paul Rennie
MD & Founder
SPONSORED BY The Market Online